RecruitingPhase 1NCT05433142

Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma

A Phase 1 Multiple Dose Study to Evaluate the Safety and Tolerability of XmAb819 in Subjects With Relapsed or Refractory Clear Cell Renal Cell Carcinoma

Sponsor

Xencor, Inc.

Enrollment

307 participants

Start Date

Jun 13, 2022

Study Type

INTERVENTIONAL

Conditions

Clear Cell Renal Cell Carcinoma

Summary

The purpose of this study is to assess the safety and tolerability of XmAb®819 administered intravenous (IV) or subcutaneous (SC) in subjects with relapsed or refractory clear cell renal cell carcinoma and to identify the minimum safe and biologically active dose and the recommended dose (RD).

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is testing a new drug called XmAb819 in people with advanced kidney cancer (clear cell renal cell carcinoma) and other solid tumors. The drug targets a protein found on certain cancer cells and is designed to help the immune system destroy them. **You may be eligible if:** - You have advanced or metastatic clear cell kidney cancer, or certain other solid tumors (including papillary kidney cancer, non-small cell lung cancer, or colorectal cancer) - Your cancer has progressed despite standard treatments - You are in good physical condition (ECOG score 0 or 1, meaning you are fully active or able to do light work) - Tumor tissue samples are available for testing **You may NOT be eligible if:** - You have previously been treated with a drug targeting the ENPP3/CD203c protein - You have a history of serious allergic reactions to antibody therapies - You received cancer treatment within the past few weeks Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BIOLOGICALXmAb819

Monoclonal Bispecific Antibody

Locations(23)

Xencor Investigative Site

Phoenix, Arizona, United States

Xencor Investigative Site

Duarte, California, United States

Xencor Investigative Site

Sacramento, California, United States

Xencor Investigative Site

New Haven, Connecticut, United States

Xencor Investigative Site

Jacksonville, Florida, United States

Xencor Investigative Site

Atlanta, Georgia, United States

Xencor Investigative Site

Chicago, Illinois, United States

Xencor Investigative Site

Chicago, Illinois, United States

Xencor Investigative Site

Louisville, Kentucky, United States

Xencor Investigative Site

Rochester, Minnesota, United States

Xencor Investigative Site

New Brunswick, New Jersey, United States

Xencor Investigative Site

New York, New York, United States

Xencor Investigative Site

New York, New York, United States

Xencor Investigative Site

Charlotte, North Carolina, United States

Xencor Investigative Site

Durham, North Carolina, United States

Xencor Investigative Site

Cincinnati, Ohio, United States

Xencor Investigative Site

Columbus, Ohio, United States

Xencor Investigative Site

Oklahoma City, Oklahoma, United States

Xencor Investigative Site

Nashville, Tennessee, United States

Xencor Investigative Site

Seattle, Washington, United States

Xencor Investigative Site

Villejuif, France

Xencor Investigative Site

Madrid, Spain

Xencor Investigative Site

Cambridge, Cambridgeshire, United Kingdom

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05433142

Related Trials

A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors

NCT0553614125 locations

Adding a Live Biotherapeutic Product (CBM588) to Pembrolizumab for the Treatment of Renal Cell Cancer After Surgery

NCT070370042 locations

Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer

NCT0722741549 locations

Phase 1b/2 Study of Combination 177Lu Girentuximab Plus Cabozantinib and Nivolumab in Treatment naïve Patients With Advanced Clear Cell RCC

NCT056637101 location

Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors

NCT036822893 locations